Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Roshini Claire Anthony, 25 Jun 2020

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.

Original New Drug Application Approvals by US FDA (16 - 31 May 2020)

02 Jun 2020
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

FERRIPROX
  • Active Ingredient(s): Deferiprone
  • Strength: 1,000 mg
  • Dosage Form(s) / Route(s): Tablet; oral
  • Company: Apopharma, Inc.
  • Approval Date: 19 May 2020
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
  • Approved Label19 May 2020 (PDF)

IMPEKLO
  • Active Ingredient(s): Clobetasol propionate
  • Strength: 0.05% w/w
  • Dosage Form(s) / Route(s): Lotion; topical
  • Company: Mylan
  • Approval Date: 19 May 2020
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, in patients 18 years of age or older.
  • Approved Label19 May 2020 (PDF)

KYNMOBI
  • Active Ingredient(s): Apomorphine hydrochloride
  • Strength: 10 mg; 15 mg; 20 mg; 25 mg; 30 mg
  • Dosage Form(s) / Route(s): Film; sublingual
  • Company: Sunovion Pharms, Inc.
  • Approval Date: 21 May 2020
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated for the acute, intermittent treatment of "off" episodes in patients with Parkinson's disease.
  • Approved Label21 May 2020 (PDF)

CERIANNA
  • Active Ingredient(s): Fluoroestradiol f18
  • Strength: 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL)
  • Dosage Form(s) / Route(s): Injectable; injection
  • Company: Zionexa US Corp
  • Approval Date: 20 May 2020
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.
  • Approved Label20 May 2020 (PDF)

PHEXXI
  • Active Ingredient(s): Lactic acid; citric acid; potassium bitartrate
  • Strength: 5 g
  • Dosage Form(s) / Route(s): Gel; vaginal
  • Company: Evofem, Inc.
  • Approval Date: 22 May 2020
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
  • Approved Label22 May 2020 (PDF)

VESICARE LS
  • Active Ingredient(s): Solifenacin succinate
  • Strength: 5 mg/5 mL (1 mg/mL)
  • Dosage Form(s) / Route(s): Suspension; oral
  • Company: Astellas
  • Approval Date: 26 May 2020
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated for the treatment of neurogenic detrusor overactivity in pediatric patients aged 2 years and older.
  • Approved Label26 May 2020 (PDF)

ARTESUNATE
  • Active Ingredient(s): Artesunate
  • Strength: 110 mg
  • Dosage Form(s) / Route(s): Injectable; injection
  • Company: Amivas, LLC
  • Approval Date: 26 May 2020
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
  • Approved Label26 May 2020 (PDF)

TAUVID
  • Active Ingredient(s): Flortaucipir f18
  • Strength: 370 MBq (10 mCi)
  • Dosage Form(s) / Route(s): Injectable; injection
  • Company: Avid Radiopharms, Inc.
  • Approval Date: 28 May 2020
  • Submission Classification: Type 1 - New Molecular Entitiy
  • Indication(s): Indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease.
  • Approved Label28 May 2020 (PDF)

ZILXI
  • Active Ingredient(s): Minocycline
  • Strength: 1.5%
  • Dosage Form(s) / Route(s): Fiber, extended release; periodontal
  • Company: Foamix
  • Approval Date: 28 May 2020
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for the treatment of inflammatory lesions of rosacea in adults.
  • Approved Label28 May 2020 (PDF)

ORIAHNN
  • Active Ingredient(s): Elagolix; estradiol norethindrone acetate; elagolix
  • Strength: 300 mg; 1 mg; 0.5 mg; 300 mg
  • Dosage Form(s) / Route(s): Capsule; oral
  • Company: Abbvie, Inc.
  • Approval Date: 29 May 2020
  • Submission Classification: Type 4 - New Combination
  • Indication(s): Indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
  • Approved Label29 May 2020 (PDF)

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Roshini Claire Anthony, 25 Jun 2020

Patients with rheumatoid arthritis (RA) treated with tumour necrosis factor (TNF) inhibitors may have a reduced risk of venous thromboembolism (VTE) compared with those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), according to an observational study presented at EULAR 2020.